Division of Clinical Cancer Genetics, Beckman Research Institute at the City of Hope National Medical Center, Duarte, California, United States of America.
PLoS One. 2011;6(9):e25632. doi: 10.1371/journal.pone.0025632. Epub 2011 Sep 28.
BRCA1 and BRCA2 are the most well-known breast cancer susceptibility genes. Additional genes involved in DNA repair have been identified as predisposing to breast cancer. One such gene, RAD51C, is essential for homologous recombination repair. Several likely pathogenic RAD51C mutations have been identified in BRCA1- and BRCA2-negative breast and ovarian cancer families. We performed complete sequencing of RAD51C in germline DNA of 286 female breast and/or ovarian cancer cases with a family history of breast and ovarian cancers, who had previously tested negative for mutations in BRCA1 and BRCA2. We screened 133 breast cancer cases, 119 ovarian cancer cases, and 34 with both breast and ovarian cancers. Fifteen DNA sequence variants were identified; including four intronic, one 5' UTR, one promoter, three synonymous, and six non-synonymous variants. None were truncating. The in-silico SIFT and Polyphen programs were used to predict possible pathogenicity of the six non-synonomous variants based on sequence conservation. G153D and T287A were predicted to be likely pathogenic. Two additional variants, A126T and R214C alter amino acids in important domains of the protein such that they could be pathogenic. Two-hybrid screening and immunoblot analyses were performed to assess the functionality of these four non-synonomous variants in yeast. The RAD51C-G153D protein displayed no detectable interaction with either XRCC3 or RAD51B, and RAD51C-R214C displayed significantly decreased interaction with both XRCC3 and RAD51B (p<0.001). Immunoblots of RAD51C-Gal4 activation domain fusion peptides showed protein levels of RAD51C-G153D and RAD51C-R214C that were 50% and 60% of the wild-type, respectively. Based on these data, the RAD51C-G153D variant is likely to be pathogenic, while the RAD51C- R214C variant is hypomorphic of uncertain pathogenicity. These results provide further support that RAD51C is a rare breast and ovarian cancer susceptibility gene.
BRCA1 和 BRCA2 是最著名的乳腺癌易感基因。其他参与 DNA 修复的基因也被确定为乳腺癌的易患因素。RAD51C 就是这样一个基因,它对同源重组修复至关重要。在 BRCA1 和 BRCA2 阴性的乳腺癌和卵巢癌家族中,已经发现了几种可能的致病性 RAD51C 突变。我们对 286 名有乳腺癌和/或卵巢癌家族史的女性乳腺癌和/或卵巢癌病例的生殖系 DNA 进行了 RAD51C 完整测序,这些病例先前 BRCA1 和 BRCA2 突变检测均为阴性。我们筛查了 133 例乳腺癌病例、119 例卵巢癌病例和 34 例同时患有乳腺癌和卵巢癌的病例。共发现 15 种 DNA 序列变异,包括 4 种内含子、1 种 5'UTR、1 种启动子、3 种同义突变和 6 种非同义突变。没有截断突变。我们使用在线 SIFT 和 Polyphen 程序根据序列保守性预测 6 种非同义突变的可能致病性。G153D 和 T287A 被预测为可能具有致病性。另外两个变体 A126T 和 R214C 改变了蛋白质的重要结构域中的氨基酸,因此可能具有致病性。我们进行了双杂交筛选和免疫印迹分析,以评估这四种非同义变体在酵母中的功能。RAD51C-G153D 蛋白与 XRCC3 或 RAD51B 均无明显相互作用,而 RAD51C-R214C 与 XRCC3 和 RAD51B 的相互作用明显减少(p<0.001)。RAD51C-Gal4 激活结构域融合肽的免疫印迹显示,RAD51C-G153D 和 RAD51C-R214C 的蛋白水平分别为野生型的 50%和 60%。基于这些数据,RAD51C-G153D 变体很可能是致病性的,而 RAD51C-R214C 变体是功能降低的,致病性不确定。这些结果进一步支持 RAD51C 是一种罕见的乳腺癌和卵巢癌易感基因。